InSphero and NCATS to Present Collaborative 3D Cancer Screening Study at SLAS2016 Annual Meeting
Schlieren, Switzerland, January 15, 2016 – Study describes high-throughput compatible screening assay using 3D tumor microtissue models to classify efficacy, toxicity, and mechanism of action for compounds in NIH Oncology Library.
InSphero AG, the leading supplier of easy-to-use solutions for the production, culture, and assessment of organotypic 3D cell culture models, will present preliminary findings from studies in collaboration with the NIH National Center for Advancing Translational Sciences (NCATS) and NMI Technologietransfer GmbH, at next week’s annual meeting of the Society for Laboratory Automation and Screening (SLAS2016) in San Diego, California. Data summarizing screens of 40 compounds from the NCATS Oncology Library in 3D ovarian and pancreatic tumor microtissues will be presented by InSphero CSO and co-founder Dr. Jens Kelm during Monday afternoon’s Assay Development & Screening poster session.
InSphero and NCATS announced a collaboration in 2014 to develop improved phenotypic high-throughput screening (HTS) methodologies incorporating more biologically relevant 3D tumor microtissue models that more closely mimic the in vivo tumor microenvironment than 2-dimensional monolayer cell culture. 3D tumor microtissue co-cultures from ovarian or pancreatic tumor cell lines in combination with stromal fibroblasts were generated using InSphero’s patented hanging drop technology.
Stromal fibroblasts were engineered to express a secreted reporter to simultaneously assess both anti-tumor efficacy and non-specific cytotoxicity. Initial findings from the collaboration include data confirming more than 50% of the 40 compounds tested displayed greater potency against ovarian and pancreatic tumor cells grown as 3D microtissues compared to the same cells grown in monolayer. Furthermore, the screen identified 3 compounds that showed anti-tumor efficacy in ovarian tumor microtissues only in the tumor/fibroblast co-culture model, highlighting the potential importance of mimicking the heterogeneous tumor microenvironment when conducting such high-throughput in vitro screens.
Dr. Kelm notes that incorporating advanced multi-cell type 3D models derived from these and other types of cancer is critical to improving the translational value of in vitro screens. “Here, we’ve established a multi-parametric phenotypic screening method that factors in tumor size and cell viability and can also discriminate between anti-tumor and non-specific toxic effects of the compounds. Based on these results, we are able to assign a therapeutic index value by which compounds are ranked for their potential efficacy and specificity toward a particular cancer, using models that more accurately reflect in vivo tumor biology.”
In addition to the poster, InSphero microtissues and high-throughput screening and imaging concepts are scheduled to be featured at SLAS2016 during a 1-day short course entitled “3D Cell-based Assays for Drug De-risking,” as well as in two Exhibitor Tutorials, and other collaborative posters.
